Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP354038.RAfe-xAeyX2terHYPd6CYjWHkfwQiKW2pEda8ovUzXbmA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP354038.RAfe-xAeyX2terHYPd6CYjWHkfwQiKW2pEda8ovUzXbmA130_assertion type Assertion NP354038.RAfe-xAeyX2terHYPd6CYjWHkfwQiKW2pEda8ovUzXbmA130_head.
- NP354038.RAfe-xAeyX2terHYPd6CYjWHkfwQiKW2pEda8ovUzXbmA130_assertion description "[In the second part, we found that the FDA-approved non-steroidal anti-inflammatory drug sulindac and its metabolites, sulindac sulfide and sulindac sulfone, increased NQO1 expression and activity in the lung adenocarcinoma cell lines CL1-1 and CL1-5, which have lower NQO1 levels and lower sensitivity to ?-lapachone treatment than the A549 cell lines, and that inhibition of NQO1 by either dicoumarol treatment or NQO1 siRNA knockdown inhibited this sulindac-induced increase in ?-lapachone cytotoxicity.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP354038.RAfe-xAeyX2terHYPd6CYjWHkfwQiKW2pEda8ovUzXbmA130_provenance.
- NP354038.RAfe-xAeyX2terHYPd6CYjWHkfwQiKW2pEda8ovUzXbmA130_assertion evidence source_evidence_literature NP354038.RAfe-xAeyX2terHYPd6CYjWHkfwQiKW2pEda8ovUzXbmA130_provenance.
- NP354038.RAfe-xAeyX2terHYPd6CYjWHkfwQiKW2pEda8ovUzXbmA130_assertion SIO_000772 24505400 NP354038.RAfe-xAeyX2terHYPd6CYjWHkfwQiKW2pEda8ovUzXbmA130_provenance.
- NP354038.RAfe-xAeyX2terHYPd6CYjWHkfwQiKW2pEda8ovUzXbmA130_assertion wasDerivedFrom befree-20150227 NP354038.RAfe-xAeyX2terHYPd6CYjWHkfwQiKW2pEda8ovUzXbmA130_provenance.
- NP354038.RAfe-xAeyX2terHYPd6CYjWHkfwQiKW2pEda8ovUzXbmA130_assertion wasGeneratedBy ECO_0000203 NP354038.RAfe-xAeyX2terHYPd6CYjWHkfwQiKW2pEda8ovUzXbmA130_provenance.